.JPG)
Heather Bradley is an Associate Professor of Epidemiology at the Emory Rollins School of Public Health. She is an infectious disease epidemiologist whose main research interests include surveillance methodology, racial disparities in HIV and hepatitis C infections, and the intersection of infectious diseases with the U.S. opioid epidemic. During the past few years, her research has focused largely on racial disparities in COVID-19 outcomes as well as the health of people who inject drugs (PWID). She previously served on the faculty at Georgia State University School of Public Health. Prior to that appointment, Dr. Bradley spent eight years at the Centers for Disease Control and Prevention in positions ranging from Epidemic Intelligence Service (EIS) Officer to Associate Chief for Science in the Division of HIV/AIDS Prevention.
Current projects:
Title: Increasing representation of Black communities in COVID-19 home testing and surveillance data (Represent ATL 2.0)
Funding agency: NIH, National Institute on Minority Health and Health Dispartities (U01MD018313); Project period: 11/01/22 – 10/31/24
Description: In this study, we are assessing knowledge and attitudes about COVID-19 home testing among diverse Black communities in Atlanta, GA, including willingness to self-collect a nasal specimen alonside traditional home testing and mail it to a laboratory for PCR testing, which facilitates reporting of results to surveillance.
Title: Increasing representation of Black communities in SARS-CoV-2 serosurveys by understanding barriers and motivations for participation (Represent ATL)
Funding agency: NIH, National Institute on Drug Abuse (3R01DA051302); Project period: 12/01/20 – 05/30/23
Description: This study aims to elucidate barriers and motivations for participating in SARS-CoV-2 research including serosurveys among diverse Black communities in Atlanta, GA.
Title: Estimating the population size of persons who inject drugs in New York
Funding agency: NIH, National Institute on Drug Abuse (R01DA051302); Project period: 04/01/20 – 01/31/25
Description: This study aims to estimate the population size of people who inject drugs (PWID) in New York State using capture-recapture and linked administrative datasets.
Title: Modeling HIV, Viral Hepatitis, STI, and TB to improve public health - CAMP 2.0: The Coalition for Applied Modeling for Prevention
Funding agency: Centers for Disease Control and Prevention (U38PS004650-01); Project period: 09/30/19 – 09/29/24
Description: As part of a multi-University modeling collaborative, my team is estimating the population size of PWID in the United States and the effects of COVID-19 on HIV and hepatitis C outcomes among PWID.
Education
- PhD 2009, Johns Hopkins Bloomberg School of Public Health
- MHS 2005, Johns Hopkins Bloomberg School of Public Health
- BA 1999, Centre College
Courses Taught
- EPI 517: Case Studies in ID EPI
- GH 517: Case Stud Infectious Dis Epid.
Affiliations & Activities
Project Director, HepVu.org
Publications
- Bradley H, Hall EW, Asher A, Furukawa N, Jones CM, Shealey J, Buchacz K, Handanagic S, Crepaz N, Rosenberg ES, 2022, Estimated number of people who inject drugs in the United States, Clinical Infectious Diseases, , Epub ahead of print
- Bradley H, Lamba K, Shioda K, Sullivan PS, Luisi N, Hall EW, Mehotra ML, Lim E, Jain S, Kamali A, Sanchez T, Lopman BA, Fahimi M, Siegler AJ, 2021, SARS-CoV-2 cumulative incidence and period seroprevalence: Results from a statewide population-based serosurvey in California, Open Forum Infectious Diseases, 8, ofab379
- Bradley H, Hall EW, Rosenthal EM, Sullivan PS, Ryerson BR, Rosenberg ES, 2020, Hepatitis C virus prevalence in 50 states and the District of Columbia by sex, birth cohort, and race/ethnicity: 2013–2016, Hepatology Communications, 14, 355 - 370
- Bradley H, Rosenthal EM, Barranco MA, Udo T, Sullivan PS, Rosenberg ES, 2020, Using national survey data to estimate the number of persons who inject drugs in the United States, Journal of Infectious Diseases, 222, S218 - 229
- Bradley H, Hogan V, Agnew-Brune C, Armstrong J, Broussard D, Buchacz K, Burton K, Cope JS, Dawson E, De La Garza G, Gerard A, Granado M, Gupta R, Haddy L, Hoffman W, Johnson SD, Kirk N, Lee C, Lyss S, Mark-Carew M, Quilter L, Reynolds P, Rose B, Thompson A, Varella L, Weidle P, White B, Wills D, Young SA, Hoots BE, 2019, Increased HIV diagnoses in West Virginia counties highly vulnerable to rapid HIV dissemination through injection drug use: A cautionary tale, Annals of Epidemiology, 34, 12 - 17
- Bradley H, Althoff KN, Buchacz K, Brooks JT, Gill MJ, Horberg MA, Kitahata MM, Marconi V, Mayer KH, Mayor A, Moore R, Mugavero M, Napravnik S, Paz-Bailey G, Prejean J, Rebeiro PF, Rentsch CT, Shouse RL, Silverberg M, Sullivan PS, Thorne JE, Yehia B, Rosenberg ES, 2019, Viral suppression among persons in HIV care during 2009–2013: Sampling bias in Medical Monitoring Project (MMP) surveillance estimates, Annals of Epidemiology, 31, 3 - 7
- Bradley H, Rosenberg ES, Holtgrave DR, 2018, Data-driven goals for curbing the U.S. HIV epidemic by 2030, AIDS and Behavior, 23, 557 - 563
- Rosenberg ES, Bradley H, Buchacz K, McKenney J, Paz-Bailey G, Prejean J, Brooks JT, Shouse RL, Sullivan PS, 2018, Improving estimation of HIV viral suppression in the United States: a method to adjust HIV surveillance estimates using cohort data, American Journal of Epidemiology, 187, 1962 - 1969
- Bradley H, Mattson CL, Beer L, Huang P, Shouse RL, 2016, Increased ART prescription and HIV viral suppression among persons receiving clinical care for HIV infection, 2009–2013, AIDS, 30, 2117 - 2124
- Bradley H, Viall AH, Wortley PM, Dempsey A, Hauck H, Skarbinski JS, 2016, Ryan White HIV/AIDS Program assistance and HIV treatment outcomes in the United States, Clinical Infectious Diseases, 62, 90 - 98